和美药业冲刺港股IPO：董事长张和胜夫妇控股46.5%，侄女婿陈英伟任董秘

Core Viewpoint - Ganzhou Hemei Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on innovative drug development for autoimmune diseases and tumors, despite not having any commercially approved products or revenue to date [2]. Company Overview - Established in 2002, Hemei Pharmaceutical is an innovation-driven biopharmaceutical company specializing in small molecule drug discovery and development [2]. - The company has developed a product pipeline consisting of seven candidate drugs, including three for autoimmune diseases and four for tumors, addressing unmet medical needs [2]. Financial Performance - Hemei Pharmaceutical has reported operating losses during the reporting period, with pre-tax losses of RMB 156 million (approximately $22.4 million) in 2023 and RMB 123 million (approximately $17.5 million) in 2024 [2]. - The majority of the losses stem from research and development expenses, as well as general and administrative costs [2]. - Research and development expenses are projected to decrease from RMB 123 million (approximately $17.5 million) in 2023 to RMB 96.98 million (approximately $13.7 million) in 2024 [2]. Shareholding Structure - Zhang Hesheng, through Ganzhou Hesheng and Ganzhou Heyi, controls approximately 25.22% of the voting rights in Hemei Pharmaceutical [5]. - Zhang Hesheng and his spouse, Guo Xuemei, collectively control about 46.51% of the company's voting rights [5]. Management Team - Zhang Hesheng, the founder and current Chairman, has over 20 years of experience in biomedical research and management [9]. - Chen Yingwei, the Executive Director and Deputy General Manager, has been with the company since 2004 and is responsible for operations, investment, and legal affairs [10].